Tourmaline Bio, Inc. (TRML)
(Real Time Quote from BATS)
$47.63 USD
+17.45 (57.82%)
Updated Sep 9, 2025 03:55 PM ET
After-Market: $47.63 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRML 47.63 +17.45(57.82%)
Will TRML be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRML
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital